Zoetis Q3 Revenue Slips 1% as U.S. Pet Sales Fall 8%, but Raises Full-Year Adjusted EPS Outlook
ZTS sits 29% above its 52-week low of $68.77 on elevated volume (1.9× avg).
Summary
Zoetis posted Q3 revenue of $2.4 billion, down 1% on both a reported and organic operational basis, with net income down 18% to $591 million and GAAP diluted EPS of $1.44. Adjusted diluted EPS came in at $1.75, up 3% reported but only 1% organically. The weak spot is the U.S.: revenue fell 6% to $1.2 billion as companion animal dropped 8% on macro-driven price sensitivity, dermatology competition and generics, while International grew 4% and livestock rose 7% company-wide. Management narrowed full-year revenue to $9.220-$9.320 billion but raised adjusted EPS guidance to $6.25-$6.35 from $6.15-$6.25, helped by a lower tax rate and trimmed R&D spend. The quarter also carried $89 million of IPR&D impairments tied to PetMedix assets and $43 million of restructuring charges, so the adjusted beat masks real GAAP pressure. Watch the 8:30 a.m. ET call for color on U.S. dermatology erosion and whether the raised EPS guide holds if companion animal stays soft.
At the time of this announcement, ZTS was trading at $88.78 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.9B. The 52-week trading range was $68.77 to $132.49. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: BusinessWire.